Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants

Research output: Contribution to journalReview articlepeer-review

23 Citations (Scopus)

Abstract

Antiphospholipid antibodies (aPL) comprise a heterogeneous group of antibodies directed against phospholipids and/or protein-complexed phospholipids. aPL are associated with the serious autoimmune condition 'antiphosholipid (antibody) syndrome' (APS) and can be defined by either 'solid-phase' assays that identify anticardiolipin antibodies (aCL) and anti-β2-glycoprotein I antibodies (aB2GPI) or 'liquid-phase' assays that identify lupus anticoagulants (LAs). There is a lack of standardization associated with all forms of aPL testing; however, intermethod and interlaboratory variation using aCL and aB2GPI assays is generally higher than that for LA testing by dRVVT (dilute russell viper venom time) procedures. Compared with either aCL or aB2GPI, LA is also more strongly associated with clinically adverse findings of APS, including thrombosis and obstetric morbidity. This review explores the potential reasons for the above findings and concludes that ultimately a more holistic approach to aPL/APS investigations is needed.

Original languageEnglish
Pages (from-to)269-74
Number of pages6
JournalInternational Journal of Laboratory Hematology
Volume35
Issue number3
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Dive into the research topics of 'Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants'. Together they form a unique fingerprint.

Cite this